Anticoagulation with warfarin or a newer anticoagulant, such as dabigatran, is required to manage this patient's long-term risk of cardioembolic stroke. ... Anticoagulation with a novel oral anticoagulant (such as dabigatran, rivaroxaban, or apixaban)
practical start-up and follow-up plans for patients taking new oral anticoagulants,. ... comparison of new anticoagulants and vitamin K antagonists in patients with AF and a malignancy.
Bleeding risk lower with aspirin vs. anticoagulation after hip fracture repair, but DVT risk may be higher
The risk of bleeding is lower with aspirin compared to anticoagulants after hip fracture surgery, but the risk of deep vein thrombosis (DVT) may be higher with aspirin, a new analysis ... Bleeding risk was lower with aspirin than anticoagulants after hip
An alternative to plasma (Prothrombin Complex Concentrate, Human; brand name, Kcentra) was approved by the FDA last week for the urgent reversal of vitamin K antagonist (VKA) anticoagulation in adults with ... Like plasma, Kcentra is used in conjunction
Anticoagulation for heart failure and afib associated with reductions in mortality, but maybe not readmissions
Starting anticoagulation for older patients with heart failure and atrial fibrillation at hospital discharge was associated with improved mortality at 1 and 3 years but was not associated with improved rates ... Among 5,105 patients in 195 hospitals,
As for atrial fibrillation, dilemmas include balancing the risks and benefits of anticoagulation and screening.
hemoglobin. Researchers recently developed a new biomarker-based bleeding risk score for patients with atrial fibrillation (AF) to help decision making about oral anticoagulation. ... The ABC-bleeding score should therefore“ be useful as decision
bleeding, and recurrent VTE rates through 30 days after starting VTE treatment (anticoagulation or filter insertion). ... The reduction of PE deaths in those with filters versus anticoagulation“ suggests that filters offer clinical benefits that are
All involved anticoagulation with oral vitamin K antagonists, with the exception of one study in which some patients received novel oral anticoagulants. ... ICH recurred in 8.7% of patients who were receiving anticoagulation and 7.8% of those who were not
Higher CHADS. 2. scores pointed to higher risk for adverse outcomes, including stroke, bleeding and death, in patients with atrial fibrillation receiving anticoagulation, according to a new study. ... However, they concluded that increasing CHADS. 2.